Finding Silent Atrial Fibrillation After Cryptogenic Stroke

A cryptogenic stroke is diagnosed when standard investigations do not identify a convincing cause. Yet an apparently unexplained ischaemic stroke may reflect intermittent atrial fibrillation (AF) that was absent during admission, too brief for a conventional Holter monitor, or overlooked among competing findings. Detecting this concealed arrhythmia matters because AF-related embolism can recur, while oral anticoagulation may substantially reduce the risk of further cardioembolic stroke in appropriately selected patients.

An implantable loop recorder (ILR), also called an insertable cardiac monitor, offers prolonged rhythm surveillance over months or years. Its value is therefore measured less by an immediate diagnostic snapshot than by the cumulative probability of capturing an AF episode. For Australian stroke services, electrophysiologists, neurologists and general practitioners, the central question is how ILR yield should influence patient selection, follow-up and treatment decisions.

Why Intermittent Atrial Fibrillation Remains Difficult To Find

Routine inpatient telemetry, a 12-lead electrocardiogram and short ambulatory monitoring can all be normal in a patient who has paroxysmal AF. Episodes may last only minutes, occur weeks apart, or emerge after the acute stroke admission. A normal ECG therefore excludes persistent AF at that moment, but it does not reliably exclude an intermittent atrial arrhythmia.

The likelihood of detection rises with the duration of monitoring. A 24-hour Holter may identify frequent episodes, whereas a seven-day or 30-day external monitor samples a larger proportion of the patient’s rhythm history. An ILR continuously monitors cardiac electrical activity and automatically stores episodes that meet programmed criteria, while also allowing symptom-triggered recordings. This extended observation is particularly useful when the clinical suspicion of embolic stroke remains high.

What Implantable Loop Recorders Add

The best-known evidence comes from CRYSTAL-AF, which compared an insertable monitor with conventional follow-up after cryptogenic stroke or transient ischaemic attack. AF detection with the implantable device was approximately 9% at six months and 12% at 12 months, compared with about 1-2% using standard monitoring. With longer follow-up, cumulative detection approached 30% at three years, illustrating why early negative tests should not be interpreted as definitive.

Other studies reinforce the role of prolonged monitoring. In PER DIEM, an ILR detected more AF over 12 months than a 30-day external loop recorder, although the absolute yield remained modest. Results vary according to the definition of AF, monitoring duration, patient age, stroke classification and the intensity of the comparator strategy. A reported detection rate is therefore not a universal promise for an individual patient.

Yield also depends on what counts as clinically meaningful AF. Some studies use an episode lasting at least 30 seconds, while clinicians may consider episode burden, recurrence, duration and the overall thromboembolic profile when discussing anticoagulation. Device algorithms can generate false positives from atrial ectopy, oversensing or noise, so stored electrograms require expert adjudication before AF is diagnosed.

Selecting Patients With The Highest Likelihood Of Yield

ILR placement is most persuasive when the stroke pattern suggests embolism and the initial work-up has been appropriately comprehensive. This commonly includes brain imaging, vascular imaging, cardiac imaging, ECG, inpatient rhythm assessment and laboratory testing directed at alternative causes. The term “cryptogenic” should represent a reasoned diagnosis rather than an incomplete evaluation.

Older age, left atrial enlargement, frequent atrial ectopy, elevated natriuretic peptides, hypertension, structural heart disease and a history of heart failure are associated with a greater probability of later AF detection. A cortical or multi-territory infarct may also heighten suspicion, although no single imaging pattern proves an atrial source. Conversely, a patient with a clear small-vessel mechanism or a competing high-risk aetiology may gain less from an ILR.

Frailty, cognition, falls, renal function, bleeding risk and medication support should be discussed before implantation. A rhythm diagnosis only improves outcomes if it leads to a safe and acceptable management plan. The Journal of Arrhythmia’s discussion of frailty assessment is relevant to this broader decision, particularly for older adults who may have several interacting vulnerabilities.

Interpreting The Time To Detection

AF detection is cumulative, not evenly distributed. Some cases appear during the first few weeks, but other patients have their initial episode many months after the stroke. This is the main advantage of an ILR over a single monitoring period: the device continues searching when external monitoring has ended and the patient has returned to ordinary activities.

A negative ILR result after a short interval should therefore be treated differently from a negative result after several years of surveillance. Even long-term monitoring cannot exclude AF absolutely, since episodes may fall below detection thresholds or be misclassified. Device clinics need systems for remote review, alert triage, battery planning, wound assessment and communication with the treating stroke team.

The timing of detection can affect care. Anticoagulation is generally considered when clinically confirmed AF is found in a patient whose estimated stroke risk and bleeding profile support treatment. The decision should account for infarct size, haemorrhagic transformation, comorbidities, renal function and patient preferences. An ILR result should prompt a structured clinical review, rather than an automatic prescription based solely on an algorithmic alert.

Australian Practice And Access Considerations

In Australia, ILR pathways often differ between metropolitan tertiary hospitals and regional or remote services. Patients in Sydney, Melbourne, Brisbane, Perth or Adelaide may have comparatively direct access to electrophysiology and device clinics, while someone in regional New South Wales, Queensland or Western Australia may face long travel, limited local cardiology coverage and difficulties attending repeated wound or interrogation appointments. Remote monitoring can reduce some travel, but it does not remove the need for reliable connectivity and clinical escalation pathways.

The Australian health system also requires practical attention to referral, hospital funding, device availability and follow-up arrangements. Local protocols may determine whether an ILR is inserted during the index admission or after outpatient review. Medication costs and access, including the patient’s eligibility for subsidised anticoagulant therapy, can influence the real-world benefit of detecting AF. These considerations should be explained in plain language rather than left to the patient after discharge.

Communication is especially important for Aboriginal and Torres Strait Islander patients, people living far from specialist centres and those who have limited access to transport or digital services. Involving family, Aboriginal health workers, primary care clinicians and local hospitals can make monitoring safer and more continuous. A technically successful implant is not a complete diagnostic pathway unless alerts, appointments and treatment decisions can be acted upon.

Balancing Benefits, Burdens And Alternatives

An ILR is a minor procedure, but it is still an invasive device. Patients should be informed about bruising, discomfort, infection, device migration, wound problems and the possibility of removal if complications occur. External patch monitors and extended event recorders may be suitable when the suspected arrhythmia is relatively frequent, when an implant is unacceptable, or when a local service cannot provide dependable long-term follow-up.

The alternative is not always “no monitoring”. A staged strategy may begin with inpatient telemetry and short-term ambulatory monitoring, followed by longer external monitoring or ILR implantation according to the clinical picture. The optimal pathway depends on stroke mechanism, expected AF burden, age, comorbid disease, patient preferences and available expertise.

Shared decision-making should address what the result would change. If confirmed AF would lead to anticoagulation, closer rhythm review or a revised diagnosis, prolonged monitoring has a clear purpose. If anticoagulation would not be appropriate because of a major contraindication or patient preference, the likely benefit of finding brief subclinical episodes may be less certain and deserves careful discussion.

Improving Clinical And Research Reporting

Studies of ILR yield should describe the population, stroke classification, monitoring duration, comparator testing and AF definition in enough detail for clinicians to interpret the results. Reporting only a final percentage can obscure when episodes were found and whether they changed treatment. Researchers should also distinguish device-detected atrial high-rate episodes from electrocardiographically confirmed AF.

Important unanswered questions remain. The ideal duration of monitoring is uncertain, as is the treatment threshold for very short, device-detected episodes without previously documented clinical AF. Trials are also examining whether anticoagulation benefits selected patients with atrial high-rate episodes who have not yet met conventional AF criteria. These questions matter because detection and treatment are linked but not interchangeable.

For clinicians and investigators preparing work in this field, the journal’s author guidelines provide the appropriate route for understanding submission requirements and reporting expectations. High-quality evidence can help Australian services decide which patients benefit most from an ILR and how to organise equitable long-term follow-up.

An implantable loop recorder increases the chance of finding paroxysmal AF after an unexplained ischaemic stroke, particularly when monitoring continues beyond the limits of routine testing. Its yield is shaped by patient selection, follow-up duration, device interpretation and access to responsive clinical care. Use the evidence alongside a complete stroke evaluation, document the shared decision clearly, and coordinate neurologists, cardiologists, electrophysiologists, primary care teams and patients through the full monitoring pathway. For editorial or publication-related enquiries, contact the journal.